Mark Geels | Senior Director
IAVI
Appearances:
Day 2 (21st October) @ 13:30
Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle
- How to define bacterial priorities for AMR vaccine and monoclonal antibody R&D (pathogen, region, health economics).
- Role of modelling and cost-effectiveness frameworks
- Aligning funders, PDPs, and pharma around the biggest-impact targets
last published: 14/May/26 15:05 GMT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events